The "Expert Consensus on Surgical Technique for Subretinal Injection of Gene Therapy in China (2022)" provides standardized procedures for administering gene therapy for inherited retinal diseases (IRDs). Following the approval of Luxturna in 2017, the consensus outlines precise drug delivery techniques, including a two-step method to create a subretinal fluid bubble before injection. It details necessary equipment, preoperative preparations, surgical steps, and addresses potential complications, aiming to standardize practices among clinicians and support advancements in retinal gene therapy in China.